|
시장보고서
상품코드
2024608
RNA 간섭 약물전달 시장 보고서 : 용도, 기술, 지역별(2026-2034년)RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2026-2034 |
||||||
세계의 RNA 간섭(RNAi) 약물전달 시장 규모는 2025년에 1,175억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 5,042억 달러에 달하며, 2026-2034년에 CAGR 17.04%로 성장할 것으로 예측하고 있습니다.
RNAi 약물전달은 유전자 발현 및 돌연변이 모니터링을 위한 치료 솔루션을 말합니다. RNAi 약물전달은 일반적으로 정맥 주사, 피내 주사, 복강내 주사, 국소 투여 방법을 통해 이루어집니다. 여기에는 나노입자, 폐, 핵산, 압타머를 이용한 약물전달 기술이 포함됩니다. 이러한 기술은 진핵생물의 유전자 기능 분석 및 치료용 유전자 침묵 솔루션 개발에도 활용되고 있습니다. 그 결과, RNAi 약물전달 기술은 감염성 질환, 만성 대사성 질환, 심혈관 질환, 신경질환, 비뇨기 질환, 종양 질환, 안과 질환의 치료에 널리 활용되고 있습니다.
전 세계에서 암, 심혈관질환(CVD) 등 만성질환 및 유전성 질환의 유병률이 증가하고 있는 것은 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한 이러한 질병에 걸리기 쉬운 고령 인구의 증가도 시장 성장을 촉진하고 있습니다. 이에 따라 신종 코로나바이러스 감염증(COVID-19)이 전 세계에서 확산되면서 RNAi 약물전달 기술에 대한 수요가 크게 증가하고 있습니다. 압타머 약물전달시스템과 같은 표적전달법은 바이러스 항원의 발현을 억제할 수 있는 소간섭 RNA(siRNA)에 의해 유도되므로 항바이러스제 투여에 있으며, 큰 주목을 받고 있습니다. 또한 혁신적인 합성 전달 캐리어 및 바이오 벡터 개발 등 다양한 기술 발전이 시장 성장을 촉진할 것으로 예상됩니다. siRNA와 마이크로RNA(miRNA)를 포함한 나노 캐리어는 개인맞춤형 의료 개발 및 변화된 세포분자와 대사산물의 규명에 매우 중요합니다. 나노테크놀러지 및 분자진단 부문의 광범위한 연구개발(R&D) 활동과 더불어 전반적인 헬스케어 인프라의 개선과 같은 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 RNA 간섭 약물전달 시장
제6장 시장 내역 : 용도별
제7장 시장 내역 : 기술별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porters Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSA 26.05.18The global RNA interference (RNAi) drug delivery market size reached USD 117.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 504.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.04% during 2026-2034.
Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.
The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Application:
- Infectious Disease
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Urology
- Metabolic Disorders
- Others
Breakup by Technology:
- Nanoparticle Drug Delivery
- Pulmonary Drug Delivery
- Nucleic Acid Drug Delivery
- Aptamer Drug Delivery
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global RNA interference (RNAi) drug delivery market with detailed profiles of all major companies, including:
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Calando Pharmaceuticals Inc
- Ionis Pharmaceuticals, Inc.
- Phio Pharmaceuticals
- Silence Therapeutics
- Sirnaomics
- Switch Therapeutics
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global RNA Interference (RNAi) Drug Delivery Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Application
- 6.1 Infectious Disease
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cardiology
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Oncology
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Neurology
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Ophthalmology
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Urology
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Metabolic Disorders
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Nanoparticle Drug Delivery
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Pulmonary Drug Delivery
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Nucleic Acid Drug Delivery
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Aptamer Drug Delivery
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Alnylam Pharmaceuticals, Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Arrowhead Pharmaceuticals, Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Calando Pharmaceuticals Inc
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Ionis Pharmaceuticals, Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Phio Pharmaceuticals
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Silence Therapeutics
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.7 Sirnaomics
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.8 Switch Therapeutics
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.1 Alnylam Pharmaceuticals, Inc.
